New COPD drug shows promise in reducing lung inflammation
NCT ID NCT05270525
First seen Feb 21, 2026 · Last updated May 21, 2026 · Updated 15 times
Summary
This study tests whether a nebulized drug called ensifentrine can reduce inflammation in the lungs of people with COPD. About 56 adults aged 40-80 who smoke or have smoked will receive both the drug and a placebo at different times to compare results. The main goal is to see changes in sputum cell counts after 8 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.